The site of interaction of opioids and inhalation anaesthetic agents is unknown, but may be at the level of the opioid receptor. In this study we have used SH-SY5Y human neuroblastoma cells, which express both and ␦ receptors, to examine Clinically, opioid drugs and inhalation anaesthetic agents are known to interact, with a significantly increased potency of inhalation agents in the presence of opioids [1] . In vivo data in rats on the interaction between morphine and halothane on movement and heart rate responses to noxious stimuli indicate that the interaction is essentially additive [2] . In vitro data, although limited, suggest that the site of interaction may be at a cellular level. Halothane dramatically potentiated the inhibitory action of morphine on acetylcholine release from the guineapig ileum preparation [3] , and potentiated the negative chronotropic effect of a specific kappa () opioid agonist on an isolated right atrial rat heart preparation [4] .
Clinically, opioid drugs and inhalation anaesthetic agents are known to interact, with a significantly increased potency of inhalation agents in the presence of opioids [1] . In vivo data in rats on the interaction between morphine and halothane on movement and heart rate responses to noxious stimuli indicate that the interaction is essentially additive [2] . In vitro data, although limited, suggest that the site of interaction may be at a cellular level. Halothane dramatically potentiated the inhibitory action of morphine on acetylcholine release from the guineapig ileum preparation [3] , and potentiated the negative chronotropic effect of a specific kappa () opioid agonist on an isolated right atrial rat heart preparation [4] .
Only a few studies have examined if inhalation anaesthetic agents influence the binding of opioids to opioid receptors, and evidence to date is contradictory. Two early studies using rat brain homogenates [5, 6] found no interaction between halothane and mu () opioid receptors, whereas a later study using guineapig brain [7] demonstrated that halothane inhibited both and opioid receptor binding. Nitrous oxide has been reported to inhibit agonist binding [8] , to have specific agonist activity [9] or to have no effect [5] on opioid binding. When considering the structural similarity of all the G protein-coupled receptors [10] , it is hard to reconcile marked inhibitory effects of halothane on opioid binding (as reported in [7] ) with reports that adrenergic and muscarinic receptors appear relatively resistant to clinical concentrations of halothane [11] .
A potentiating effect of anaesthetic agents on opioid-receptor interaction could explain the welldocumented [1, [12] [13] [14] reduction in the MAC values of inhalation anaesthetics in the presence of opioids. Alternatively, the biochemical explanation of this inhalation anaesthetic-opioid interaction may lie more distally in the opioid signal transduction pathway: at the G protein, at the effector enzymes, adenyl cyclase, phospholipase C, or both, or at ion channels. In either case, it is necessary to see if there is an effect of inhalation anaesthetics at the level of the opioid receptor before further investigation of the possible interaction of anaesthetic agents with opioid intracellular pathways.
In this study we have used SH-SY5Y human neuroblastoma cells, which express both and delta (␦) receptors [15] ): air containing 0.5-5.0 % v/v halothane, delivered by a calibrated Fluotec 3 vaporizer; 75 % nitrous oxide in 25 % oxygen; or air alone. The concentration of anaesthetic agent delivered was checked regularly using an anaesthetic agent monitor (Capnomac) or oxygen analyser. Buffer concentrations of halothane were measured by gas chromatography [16] and showed that equilibrium was reached within 10 min. The aqueous halothane concentrations following pre-equilibration (15 min) are shown in table 1. Gas delivery was continued throughout the 60-min incubation period.
Bound and free radioactivity were separated by rapid vacuum filtration using a Brandel cell harvester onto Whatman GF/B filters and washed with 3 ϫ 4-ml aliquots of ice-cold buffer. Protein concentrations were determined according to the method of Lowry and colleagues [17] . Radioactivity was extracted overnight and measured by liquid scintillation spectroscopy.
DATA ANALYSIS Saturation curves were analysed according to Scatchard [18] to yield the equilibrium dissociation constant (Kd) and maximum binding capacity (Bmax). In displacement experiments, the concentration of displacer producing 50 % displacement of specific binding (IC50) was obtained by computerassisted curve-fitting using GRAPHPAD (v 2.0), and corrected for the competing mass of [ 
Results
The binding of both [ Nitrous oxide 75 % had no effect on [ (table 3) was unaffected by 1.0 % halothane, but was inhibited by 5.0 % halothane, with a modest increase in Kd from Table 1 Aqueous halothane concentrations estimated by gas chromatography, and equivalent % atm values (mean (SEM) n : 4). Halothane was equilibrated by surface "blowing" over 1 ml of buffer solution at 37 °C. The equivalent % atm is calculated assuming that 1.0 % atm halothane at equilibration with aqueous phase produces a concentration of 280 mol litre 91 [22] Vaporizer dial setting (%) 91 for morphine (n : 5) and 11.1 (1.6) nmol litre 91 for fentanyl (n : 7). Halothane 5.0 % had no effect on the binding of either opioid.
Discussion
We have demonstrated that opioid binding in SH-SY5Y cells and membranes was relatively unaffected by clinical concentrations of nitrous oxide and halothane. Neither nitrous oxide nor halothane had any effect on the binding of [ 3 H]DPN, the nonselective opioid antagonist, suggesting that there was no influence of nitrous oxide or halothane on either or ␦ receptor binding. The small decrease in binding affinity of the selective agonist DAMGO in the presence of 5.0 % halothane was similar to, but less marked than the effects of 2.0 % halothane on agonist (dihydromorphine) binding reported previously [7] . The differential effect of 5.0 % halothane on agonist vs antagonist binding is interesting but not remarkable; frequently it is found that antagonist binding is little affected by changes in, for example, sodium or guanine nucleotide concentrations, which may markedly influence agonist binding [15] . While these findings were not unexpected, it is worth considering why our results are at variance with some of these earlier investigations [7] [8] [9] .
Ori, Ford-Rice and London [7] appeared to show that 100 % nitrous oxide affects the Kd of opioid binding without affecting Bmax, but this was only in comparison with non-gassed samples. Comparison instead with their samples treated with 100 % oxygen reveals that there was no difference between the effects of nitrous oxide and oxygen on binding.
As halothane has the properties of an organic solvent (which can dissolve membranes), the importance of examining effects at clinically relevant concentrations cannot be overemphasized. Franks and Lieb [20] reviewed the methodological pitfalls of studies with inhalation anaesthetics. They stressed the importance of experimental temperature in determining the actual tissue concentration of an aesthetic and, further, the desirability of measuement of tissue concentration of anaesthetic. In the present study, anaesthetic agent was delivered continuously to the samples before and during the binding reaction. Temperature was maintained at 37 °C, and gas chromatography was used (for halothane), both to ensure that equilibrium was reached within the 15 min pre-incubation period and to confirm that the aqueous halothane concentrations were close to those expected. In contrast, the methods of Ori, Ford-Rice and London [7] were likely to result in tissue concentrations of halothane several times higher than intended [21] , because of the marked temperature dependence of water-gas partition coefficients [22] . In their study, membrane homogenate was equilibrated with halothane at 0 °C, then added to the reagents, and the mixture sealed in tubes and warmed at 25 °C. No allowance was made for the much higher solubility of halothane at lower temperatures or for the fact that the sealed tube would cause the tissue concentration at 0 °C to be maintained even when warmed to 25 °C. No attempt was made to measure aqueous concentrations, which may well have been the equivalent of 10 % halothane at a physiological temperature.
In summary, we have demonstrated only minor effects of clinical concentrations of halothane and nitrous oxide on and ␦ opioid binding; these results suggest that the site of opioid and anaesthetic agent interaction is not at the level of the opioid receptor. Further studies are currently underway to determine if there is an interaction in the opioid transduction cascade distal to the receptor.
